Apellis Pharmaceuticals, INC Form 4 insider transactions

Apellis Pharmaceuticals director A. Sinclair Dunlop was granted restricted stock units and stock options, aligning his interests with shareholders.

Apellis Pharmaceuticals director Gerald Chan was granted 7,961 restricted stock units and 14,684 stock options, effective January 1, 2026.

Apellis Pharmaceuticals director Stephanie Monaghan O'Brien was granted 7,961 restricted stock units and 14,684 stock options effective January 1, 2026.

Apellis Pharmaceuticals Director Paul R. Fonteyne was granted 7,961 restricted stock units and 14,684 stock options on January 1, 2026.

Apellis Pharmaceuticals director Keli Walbert was granted 7,961 restricted stock units and 14,684 stock options effective January 1, 2026.

Apellis Pharmaceuticals director Craig A. Wheeler was granted 7,961 restricted stock units and 14,684 stock options on January 1, 2026, as part of his compensation.

Apellis Pharmaceuticals' General Counsel, David O. Watson, sold 5,000 shares of common stock at $24.49 per share as part of a pre-arranged 10b5-1 trading plan.

Apellis Pharmaceuticals General Counsel David O. Watson sold 5,000 shares of common stock for $20.06 per share as part of a pre-arranged 10b5-1 trading plan.

Apellis Pharmaceuticals' CFO, Timothy Sullivan, executed a pre-scheduled sale of 10,000 common shares, realizing a gain from exercised stock options.

Apellis Pharmaceuticals' General Counsel, David O. Watson, reported a scheduled sale of 5,000 shares of common stock at $25.22 per share.

Apellis Pharmaceuticals director, A. Sinclair Dunlop, reported stock transfers and sales, significantly reducing his indirect beneficial ownership through Epidarex.

Apellis Pharmaceuticals Director Sinclair Dunlop sold 31,092 shares of common stock and distributed 3,837 shares, primarily through an indirect holding via Epidarex Capital I LP.

Apellis Pharmaceuticals Director A. Sinclair Dunlop reported the sale of 31,092 common shares and a distribution of 3,837 shares, primarily through an indirect holding.

Apellis Pharmaceuticals General Counsel David O. Watson sold 5,000 shares of common stock for $24.34 per share as part of a pre-arranged 10b5-1 trading plan.

Apellis Pharmaceuticals' VP/Chief Accounting Officer, James Chopas, sold 189 shares of common stock to cover tax obligations related to RSU vesting.

Apellis Pharmaceuticals General Counsel David O. Watson reported a planned sale of 20,000 shares of common stock for approximately $26.17 per share, effective September 10, 2025.

Apellis Pharmaceuticals' CFO, Timothy Sullivan, executed a pre-scheduled sale of common stock following the exercise of options.

Apellis Pharmaceuticals' VP/Chief Accounting Officer, James Chopas, sold 548 shares of common stock to cover tax withholding on Restricted Stock Units.

Apellis Pharmaceuticals' Chief People Officer, Kelley Boucher, was granted 30,476 restricted stock units and options for 45,766 shares, effective September 2, 2025.

Apellis Pharmaceuticals' Chief Research and Development Officer, Leslie Meltzer, received significant equity awards, including restricted stock units and stock options, on August 26, 2025.

Apellis Pharmaceuticals CEO Cedric Francois reported the sale of 225,000 shares of common stock in late August 2025, executed under a Rule 10b5-1 plan.

Apellis Pharmaceuticals' General Counsel, David O. Watson, sold 5,000 shares of common stock for $27.80 per share as part of a pre-arranged 10b5-1 trading plan.

Apellis Pharmaceuticals CEO Cedric Francois reported the exercise of stock options and the sale of common stock totaling 19,725 shares, executed under a pre-arranged 10b5-1 trading plan.

Apellis Pharmaceuticals' General Counsel, David O. Watson, sold 5,000 shares of common stock for $19.55 per share as part of a pre-scheduled 10b5-1 trading plan.

Apellis Pharmaceuticals CEO Cedric Francois disclosed the exercise of stock options and subsequent sale of company shares totaling over $2.8 million, executed under a pre-arranged 10b5-1 trading plan.

Apellis Pharmaceuticals, Inc. announced that its VP/Chief Accounting Officer, James George Chopas, was granted 6,250 restricted stock units with a future grant date of June 18, 2025.

Apellis Pharmaceuticals' General Counsel, David O. Watson, filed a Form 4 disclosing the sale of 5,000 shares of common stock at $18.77 per share, executed as part of a pre-established 10b5-1 trading plan.

Kelley Boucher, Chief People Officer of Apellis Pharmaceuticals, Inc., was granted 45,095 Restricted Stock Units and 67,396 stock options, aligning her interests with long-term shareholder value.

Apellis Pharmaceuticals, Inc. has disclosed a new stock option grant to its General Counsel, David O. Watson, as part of his compensation package.

Apellis Pharmaceuticals' Chief Technical Officer, Nur Nicholson, was granted 82,500 stock options with an exercise price of $19.39, vesting over two years.